Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation-Reference-Cited by-同舟云学术

Patient- reported reasons for non-participation in a COVID-19 therapeutics clinical trial: Findings from a multi-center investigation

Published:2023-03 Issue: Volume:126 Page:107082
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Dassum Samira Reyes,Ferguson Ryan,Woods Patricia,Flynn Maura,Visnaw Karen,Holmberg Erika,Schiller Sara,Shannon Colleen,Brophy Mary,Monach Paul,Leatherman Sarah,Branch-Elliman Westyn

Funder

Gilead Sciences

Health Services Research and Development

National Institutes of Health

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference31 articles.

1. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome;Le;Oncologist,2018

2. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. De Socio GV, ed;Branch-Elliman;PLoS One,2022

3. Trends in COVID-19 therapeutic clinical trials;Bugin;Nat. Rev. Drug Discov.,2021

4. Public participation in, and awareness about, medical research opportunities in the era of clinical and translational research: awareness about medical research in the era of clinical and translational research;Davis;Clin Transl Sci.,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization;Annals of Internal Medicine;2023-04